Andrew Lindsley
YOU?
Author Swipe
View article: Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study
Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study Open
View article: Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses
Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses Open
This is a pooled analysis of 2 studies registered at Clinicaltrials.gov: PATHWAY (NCT02054130) and NAVIGATOR (NCT03347279).
View article: Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study
Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study Open
View article: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study Open
ClinicalTrials.gov identifier, NCT05329194.
View article: Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma
Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma Open
These findings suggest that there may be differential effects of biologics in reducing exacerbations that require hospitalization or an ED visit in patients with moderate or severe, uncontrolled asthma.
View article: Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR
Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR Open
View article: Real-world Outcomes Following Biologic Initiation in US Patients with Chronic Rhinosinusitis with Nasal Polyps
Real-world Outcomes Following Biologic Initiation in US Patients with Chronic Rhinosinusitis with Nasal Polyps Open
View article: Asthma Biologics Across the T2 Spectrum of Inflammation in Severe Asthma: Biomarkers and Mechanism of Action
Asthma Biologics Across the T2 Spectrum of Inflammation in Severe Asthma: Biomarkers and Mechanism of Action Open
Airway inflammation, a hallmark feature of asthma, drives many canonical features of the disease, including airflow limitation, mucus plugging, airway remodeling, and hyperresponsiveness. The T2 inflammatory paradigm is firmly established …
View article: Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE Study
Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE Study Open
NCT03373045.
View article: Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study Open
NAVIGATOR (NCT03347279).
View article: KMT2D regulates activation, localization, and integrin expression by T-cells
KMT2D regulates activation, localization, and integrin expression by T-cells Open
Individuals with Kabuki syndrome present with immunodeficiency; however, how pathogenic variants in the gene encoding the histone-modifying enzyme lysine methyltransferase 2D (KMT2D) lead to immune alterations remain poorly understood. Fol…
View article: Gaps in Care Among Uncontrolled Severe Asthma Patients in the United States
Gaps in Care Among Uncontrolled Severe Asthma Patients in the United States Open
A substantial proportion of uncontrolled patients with SA had no evidence of specialist visits or medication escalation after uncontrolled disease, and there was a clear relationship between uncontrolled disease and subsequent health care …
View article: Efficacy of Biologics in Patients With Severe, Uncontrolled Asthma by Allergic Status
Efficacy of Biologics in Patients With Severe, Uncontrolled Asthma by Allergic Status Open
View article: Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma With Aspirin-exacerbated Respiratory Disease: Results From the NAVIGATOR Study
Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma With Aspirin-exacerbated Respiratory Disease: Results From the NAVIGATOR Study Open
View article: Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma and Fungal Sensitization
Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma and Fungal Sensitization Open
View article: Biologic Outcomes by Presence of Clinically Relevant Allergy: Results From The CHRONICLE Study
Biologic Outcomes by Presence of Clinically Relevant Allergy: Results From The CHRONICLE Study Open
View article: Efficacy of Biologics in Patients With Moderate-to-Severe, Uncontrolled Asthma and Nasal Polyps
Efficacy of Biologics in Patients With Moderate-to-Severe, Uncontrolled Asthma and Nasal Polyps Open
View article: Table of Contents
Table of Contents Open
View article: LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX
LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX Open
View article: Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR) Open
ClinicalTrials.gov Identifier: NCT03347279 (https://clinicaltrials.gov/ct2/show/NCT03347279).
View article: Incremental cost burden among patients with severe uncontrolled asthma in the United States
Incremental cost burden among patients with severe uncontrolled asthma in the United States Open
BACKGROUND: The economic burden of severe asthma and severe uncontrolled asthma (SUA) is significant. Updated assessments of health care resource utilization (HCRU) and cost are needed given the increase in treatment options and upd…
View article: Tezepelumab Reduces Exacerbations Across All Seasons In Patients With Severe, Uncontrolled Asthma With Seasonal Allergy: Results From The Phase 3 NAVIGATOR Study
Tezepelumab Reduces Exacerbations Across All Seasons In Patients With Severe, Uncontrolled Asthma With Seasonal Allergy: Results From The Phase 3 NAVIGATOR Study Open
View article: Efficacy Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Specific Perennial Allergen Immunoglobulin E Thresholds
Efficacy Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Specific Perennial Allergen Immunoglobulin E Thresholds Open
View article: KMT2D Regulates thymic Egress by Modulating Maturation and integrin Expression
KMT2D Regulates thymic Egress by Modulating Maturation and integrin Expression Open
Objective There is a clinical need to understand how dysregulated thymocyte development, caused by pathogenic variants in the gene encoding the histone-modifying enzyme, lysine methyltransferase 2D ( KMT2D ), contributes to immune dysfunct…
View article: Increased nasal epithelial cell responsiveness to IL‐17A in paediatric asthmatics with low blood neutrophil count, low traffic‐related air pollution exposure and good asthma control
Increased nasal epithelial cell responsiveness to IL‐17A in paediatric asthmatics with low blood neutrophil count, low traffic‐related air pollution exposure and good asthma control Open
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
View article: CEA 2021-0486 Supplemental Data
CEA 2021-0486 Supplemental Data Open
Supplemental Data for CEA 2021-0486
View article: CEA 2021-0486 Supplemental Data
CEA 2021-0486 Supplemental Data Open
Supplemental Data for CEA 2021-0486
View article: Lysine methyltransferase 2D regulates muscle fiber size and muscle cell differentiation
Lysine methyltransferase 2D regulates muscle fiber size and muscle cell differentiation Open
Kabuki syndrome (KS) is a rare genetic disorder caused primarily by mutations in the histone modifier genes KMT2D and KDM6A . The genes have broad temporal and spatial expression in many organs, resulting in complex phenotypes observed in …
View article: Increased responsiveness to IL-17A in pediatric asthmatics with high IgE, low traffic related air pollution exposure, and good asthma control
Increased responsiveness to IL-17A in pediatric asthmatics with high IgE, low traffic related air pollution exposure, and good asthma control Open
increased-responsiveness-to-il-17a-in-pediatric-asthmatics-with-highige-low-traffic-related-air-pollution-exposure-and
View article: Clinical testing for COVID-19
Clinical testing for COVID-19 Open